Drug intelligence / Profile preview

Hemay5259

Development stage: Phase 1
Lead developer: Tianjin Hemay Biotech
Modality: Small Molecules
Administration: Oral

Overview

Hemay5259 is an investigational extended-release oral medication being developed by Hemay Pharmaceutical. It is currently in early-stage clinical development, with Phase 1 studies focused on evaluating its safety, tolerability, and pharmacokinetic profile, including the impact of food on drug absorption, in healthy volunteers. While the specific molecular target has not been publicly disclosed in trial registries, the drug is formulated as an extended-release tablet, suggesting a therapeutic profile requiring sustained plasma concentrations.

Beyond the preview

Go deeper on Hemay5259.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemay5259.

Explore the full profile